Pattern of mortality after menopausal hormone therapy: long-term follow up in a population-based cohort

被引:11
作者
Holm, M. [1 ]
Olsen, A. [1 ]
Yeung, S. L. Au [2 ]
Overvad, K. [3 ]
Lidegaard, O. [4 ]
Kroman, N. [5 ]
Tjonneland, A. [1 ]
机构
[1] Danish Canc Soc Res Ctr, Unit Diet Genes & Environm, 49 Strandblvd, DK-2100 Copenhagen, Denmark
[2] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Peoples R China
[3] Aarhus Univ, Sect Epidemiol, Dept Publ Hlth, Aarhus, Denmark
[4] Univ Copenhagen, Juliane Marie Ctr, Gynaecol Clin, Rigshosp, Copenhagen, Denmark
[5] Univ Copenhagen, Herlev Hosp, Dept Breast Surg, Copenhagen, Denmark
关键词
all-cause mortality; cause-specific mortality; menopausal hormone therapy; time-varying mortality estimates; FOOD FREQUENCY QUESTIONNAIRE; ESTROGEN PLUS PROGESTIN; REPLACEMENT THERAPY; CANCER INCIDENCE; ESTROGEN/PROGESTIN REPLACEMENT; COLORECTAL-CANCER; DISEASE OUTCOMES; HEALTH; RISKS; WOMEN;
D O I
10.1111/1471-0528.15433
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective To investigate long-term pattern of mortality in menopausal women according to different modalities of hormone therapy. Design Population -based prospective cohort study. Setting Denmark 1993-2013. Population A total of 29 243 women aged 50-64 years at entry into the Diet, Cancer and Health Cohort, enrolled 1993-97 and followed through 31 December 2013. Methods Cox' proportional hazards models for increasingly longer periods of follow-up time were used to estimate mortality pattern according to baseline hormone use adjusted for relevant potential confounders. Main outcome(s) All-cause and cause-specific mortality. Outcome information was obtained from the Danish Register of Causes of Death (linkage 99.6%). Results A total of 4098 women died during a median follow up of 17.6 years. After adjustment for relevant lifestyle risk factors, hormone use had no impact on all-cause mortality, regardless of modality. Among baseline users, lower cardiovascluar disease mortality was only evident after 5 years [hazard ratio (HR) 0.54; 95% CI 0.32-0.92], but dissipated with additional follow up. Conversely, lower colorectal cancer mortality (HR 0.64; 95% CI 0.46-0.89) and higher breast cancer mortality (HR 1.34; 95% CI 1.05-1.72) only became evident after 15 years of follow up. There were no significant associations for mortality from other types of cancer or from stroke. Conclusions In this long-term follow-up study, taking hormones during menopause was not associated with overall mortality among middle-aged women. Investigating cause-specific mortality revealed significant, albeit weak, differential associations according to both causes of death and over time, underlining the importance of carefully considering individual risks and duration of treatment when making decisions on hormone therapy.
引用
收藏
页码:55 / 63
页数:9
相关论文
共 40 条
[1]   Competing risks in epidemiology: possibilities and pitfalls [J].
Andersen, Per Kragh ;
Geskus, Ronald B. ;
de Witte, Theo ;
Putter, Hein .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2012, 41 (03) :861-870
[2]   Colorectal cancer in women: hormone replacement therapy and chemoprevention [J].
Barnes, E. L. ;
Long, M. D. .
CLIMACTERIC, 2012, 15 (03) :250-255
[3]   Menopausal Hormone Therapy and Mortality: A Systematic Review and Meta-Analysis [J].
Benkhadra, Khalid ;
Mohammed, Khaled ;
Al Nofal, Alaa ;
Leon, Barbara G. Carranza ;
Alahdab, Fares ;
Faubion, Stephanie ;
Montori, Victor M. ;
Abu Dabrh, Abd Moain ;
Hernandez, Jorge Alberto Zuniga ;
Prokop, Larry J. ;
Murad, Mohammad Hassan .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (11) :4021-4028
[4]   Breast tumours following combined hormone replacement therapy express favourable prognostic factors [J].
Borgquist, Signe ;
Anagnostaki, Lola ;
Jirstrom, Karin ;
Landberg, Goran ;
Manjer, Jonas .
INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (10) :2202-2207
[5]   Evidence-based assessment of the impact of the WHI on women's health [J].
Burger, H. G. ;
MacLennan, A. H. ;
Huang, K-E. ;
Castelo-Branco, C. .
CLIMACTERIC, 2012, 15 (03) :281-287
[6]   Menopausal hormone therapy and breast cancer mortality: clinical implications [J].
Chlebowski, Rowan T. ;
Anderson, Garnet L. .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2015, 6 (02) :45-56
[7]   Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity [J].
Chlebowski, Rowan T. ;
Anderson, Garnet L. .
STEROIDS, 2014, 90 :53-59
[8]   Changing Concepts: Menopausal Hormone Therapy and Breast Cancer [J].
Chlebowski, Rowan T. ;
Anderson, Garnet L. .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (07) :517-527
[9]   Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial [J].
Chlebowski, Rowan T. ;
Schwartz, Ann G. ;
Wakelee, Heather ;
Anderson, Garnet L. ;
Stefanick, Marcia L. ;
Manson, JoAnn E. ;
Rodabough, Rebecca J. ;
Chien, Jason W. ;
Wactawski-Wende, Jean ;
Gass, Margery ;
Kotchen, Jane Morley ;
Johnson, Karen C. ;
O'Sullivan, Mary Jo ;
Ockene, Judith K. ;
Chen, Chu ;
Hubbell, F. Allan .
LANCET, 2009, 374 (9697) :1243-1251
[10]  
Chlebowski RT, 2015, CLIN LUNG CANCER, V17